In-Depth Research On:
Sunesis Pharmaceuticals, Inc. (SNSS)
Sign Up Now to Download a Free Research Report on SNSS
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Sunesis Pharmaceuticals, Inc.
Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer. The company remains on track to complete enrollment in the VALOR Trial of vosaroxin in 2013, with unblinding of the study data expected in the first half of 2014.
Going forward ... (see research report)
